Avience Biomedi. — 360° view

Avience Biomedi, a company in the Medical Equipment & Supplies industry, reported revenue of ₹31 crore and net profit of ₹5.54 crore for the September 2026 quarter.

Avience Biomedi. (NSE: AVIENCE-SM) closed at ₹263.85 on 20 Nov 2026. Its market capitalisation is ₹145 crore and it trades at 14.8 times earnings.

Share price
₹263.85 (20 Nov 2026)
Market cap
₹145 Cr (20 Nov 2026)
P/E
14.83 (20 Nov 2026)
Revenue
₹31 Cr (September 2026 quarter)
Net profit
₹6 Cr (September 2026 quarter)
ROCE
27.0% (FY26)
ROE
32.3% (FY26)
Book value
₹112 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹392.00 / ₹222.00 (20 Nov 2026)
Sector
Healthcare
Industry
Medical Equipment & Supplies
Symbol
NSE: AVIENCE-SM

Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.